RVTY — Revvity, Inc.

Revvity (RVTY) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $711 million, reflecting 3% organic growth; pro forma revenue (excluding the immunodiagnostics business in China) was $687 million, equating to 6% organic growth.
• Adjusted Operating Margin: 23.6%, exceeding the 23% outlook; pro forma adjusted operating margin was 24%.
• Adjusted Earnings Per Share (EPS): $1.06, above the guidance range of $1.02 to $1.04.
• Free Cash Flow: $115 million, with a robust conversion rate of 97% of adjusted net income.
• Debt Metrics: Net debt to adjusted EBITDA ratio of 2.8x, with 100% of debt being fixed rate.

2. Strategic Updates and Business Highlights

• Divestiture of Immunodiagnostics Business: Revvity plans to divest its immunodiagnostics business in China, which represented about 6% of total revenue last year. This strategic move aims to focus resources on higher-return areas and is expected to enhance overall financial performance.
• Growth in Life Sciences: The Life Sciences segment showed solid performance, with reagents growing above overall performance and a positive outlook for continued growth in 2026.
• Software Innovations: Revvity introduced several new software platforms, including Xynthetica and BioDesign, aimed at enhancing AI-driven research capabilities.
• Market Conditions: Modest improvements in pharma and biotech spending were noted, with positive growth in academic and government sectors.

3. Forward Guidance and Outlook

• 2026 Guidance:
  • Organic growth is now expected to be in the range of 3% to 4%, reflecting the exclusion of the immunodiagnostics business.
  • Adjusted operating margins are projected at 28.4%, up 40 basis points from previous guidance.
  • Adjusted EPS is now forecasted at $5.20 to $5.30, reflecting a $0.15 reduction due to the divestiture.
• Q2 2026 Expectations: Pro forma organic growth is anticipated to be between 2% to 3%, with total revenue expected to range from $699 million to $707 million.

4. Bad News, Challenges, or Points of Concern

• China Market Challenges: The immunodiagnostics business in China faced persistent headwinds due to policy-induced issues affecting demand and pricing. The divestiture reflects ongoing challenges in this market.
• Cautious Outlook: Despite positive trends, Revvity remains prudent in its forward-looking assumptions due to potential volatility in customer spending and regulatory changes.
• Software Business Volatility: The software segment is expected to face tougher comparisons in Q2, with anticipated declines of approximately 20% in organic growth.

5. Notable Q&A Insights

• Customer Engagement: Strong engagement and excitement around new software offerings were highlighted, particularly in partnerships with major pharma companies.
• Reagents Business Stability: There are signs of improvement in the reagents business, with positive mid-single-digit growth noted, indicating a potential recovery in demand.
• Future M&A Activity: Revvity remains open to acquisitions but is currently focused on share buybacks, indicating a strategic shift towards optimizing capital allocation.
• Operational Efficiency: Cost efficiency initiatives are on track to enhance margins, with expectations for significant benefits starting in the second half of 2026.

Overall, Revvity's Q1 2026 results reflect a strong start to the year, driven by strategic divestitures and growth in key segments, while also navigating challenges in specific markets and maintaining a cautious outlook for the remainder of the year.